Dr. Priya Ramanathan

Co-founder & CEO, Aksara Biosciences

Singapore · resident; UK citizen · Biotech · clinical-stage oncology · US$ 58M

Accepted w/ conditions

Composite

34/ 100▼

Liquidity event from Aksara's NASDAQ listing, March 2026. Wealth fully documented via Form S-1 lock-up schedule and broker statements.

AI verdict

live

Current recommendation

Accept with conditions

Confidence

91%

AcceptConditionsEDDDeferDecline

Dimension scores

live

Financial Crime16/100

Source of Wealth18/100

Jurisdiction32/100

Network24/100

Reputation22/100

Commercial Valueoffset74/100

Verdict history

live

2026-06-26 13:20CommitteeAccepted w/ conditionscomposite 34
Approved subject to: (1) staged transfer over 6 months, (2) hedging plan for AKSR stock concentration.
2026-06-26 10:05AI CouncilRe-scoredcomposite 34
Source-of-wealth corroborated via SEC EDGAR cross-check.
2026-06-25 17:40AnalystNote
Lock-up confirmation letter from issuer's counsel received.